EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieVergleichsstudieOpen access · CC BY-NC 4.0

Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease

Stephanie A Vuijk iD, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek and 8 more

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18000 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2024. Written by Stephanie A Vuijk and 19 co-authors. Institution: Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands. Major MEDLINE topics: Crohn Disease, Infliximab, Cost-Benefit Analysis, Gastrointestinal Agents. Cited 11 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Pfizer, ZonMw, Erasmus MC Sophia Foundation (Crocokids project).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Data on cost‐effectiveness of first‐line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed.

Aim

To investigate the cost‐effectiveness of first‐line infliximab compared to conventional treatment in children with moderate‐to‐severe Crohn's disease.

Methods

We included patients from the Top‐down Infliximab Study in Kids with Crohn's disease randomised controlled trial. Children with newly diagnosed moderate‐to‐severe Crohn's disease were treated with azathioprine maintenance and either five induction infliximab (biosimilar) infusions or conventional induction treatment (exclusive enteral nutrition or corticosteroids). Direct healthcare consumption and costs were obtained per patient until week 104. This included data on outpatient hospital visits, hospital admissions, drug costs, endoscopies and surgeries. The primary health outcome was the odds ratio of being in clinical remission (weighted paediatric Crohn's disease activity index

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseInfliximabCost-Benefit AnalysisGastrointestinal AgentsBiosimilar PharmaceuticalsHumansMaleFemaleChildAdolescentTreatment OutcomeAzathioprineImmunosuppressive AgentsAdrenal Cortex HormonesHealth Care Costs

Substances

InfliximabGastrointestinal AgentsBiosimilar PharmaceuticalsAzathioprineImmunosuppressive AgentsAdrenal Cortex Hormones

Authors and institutions

  • Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
  • Department of Paediatric Gastroenterology, Isala Hospital, Zwolle, The Netherlands.
  • Department of Paediatric Gastroenterology, Maasstad Hospital, Rotterdam, The Netherlands.
  • Department of Paediatric Gastroenterology, UMC Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Department of Paediatric Gastroenterology, Amphia Hospital, Breda, The Netherlands.

ORCID profiles: Stephanie A Vuijk, Patrick F van Rheenen, Johanna C Escher, Lissy de Ridder

Funding

  • Pfizer
  • ZonMw
  • Erasmus MC Sophia Foundation (Crocokids project)

Cite

APA

Vuijk, S. A., Jongsma, M. M. E., Hoeven, B. M., Cozijnsen, M. A., van Pieterson, M., de Meij, T. G. J., Norbruis, O. F., Groeneweg, M., Wolters, V. M., van Wering, H., Hummel, T., Stapelbroek, J., van der Feen, C., van Rheenen, P. F., van Wijk, M. P., Teklenburg, S., Rizopoulos, D., Poley, M. J., Escher, J. C., & de Ridder, L. (2024). Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18000

Vancouver

Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, et al. Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18000

BibTeX
@article{Vuijk2024,
  author = {Vuijk, Stephanie A and Jongsma, Maria M E and Hoeven, Britt M and Cozijnsen, Maarten A and van Pieterson, Merel and de Meij, Tim G J and Norbruis, Obbe F and Groeneweg, Michael and Wolters, Victorien M and van Wering, Herbert and Hummel, Thalia and Stapelbroek, Janneke and van der Feen, Cathelijne and van Rheenen, Patrick F and van Wijk, Michiel P and Teklenburg, Sarah and Rizopoulos, Dimitris and Poley, Marten J and Escher, Johanna C and de Ridder, Lissy},
  title = {Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18000}
}
Start for free →